| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, February 1, 2019 On Dec. 10, Bristol-Myers Squibb made what it called its final offer to buy Celgene. But it turns out that wasn’t the case. Just days before a Jan. 2 deadline, with Celgene's shares reeling, Bristol-Myers pulled its $57-per-share bid—and won a lower price instead. |
|
|
| This week's sponsor is Camargo. | | | [Webinar] Maximizing the Value of Your Drug Development Program
Thursday, February 21 | 11am ET / 8am PT
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program. Register Now! |
Top Stories Of The Week Tuesday, February 5, 2019 Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition of Kite Pharma. Wednesday, February 6, 2019 GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout. Friday, February 8th, 2018 While advancements have been made, multiple myeloma remains incurable. Amgen is striving to improve the lives of patients. USA-171-80483 Friday, February 1, 2019 Merck's reliance on its blockbuster I-O drug Keytruda has worried market watchers for a while, and now that 2019 revenue expectations are on the low side, those worries have intensified. Yes, Keytruda soared 66% in the fourth quarter, but the company badly needs to diversify beyond the star drug, analysts said. Friday, February 1, 2019 Novartis had what CEO Vas Narasimhan called a transformative year in manufacturing in 2018 as it closed or sold eight facilities and restructured eight others to be more efficient. But more is in store for manufacturing over the next 18 months as Novartis transforms its generics unit Sandoz into an “autonomous unit within Novartis.” Wednesday, February 6, 2019 The ubiquitous messaging company Slack has confidentially filed for an IPO—except not-so-confidentially, as it went public with the news on its own earlier this week with a press release. Friday, February 1, 2019 Inhibiting the mTOR protein has been tried before in liver cancer but with little success. More than 20% of patients have a gene mutation that could make them particularly responsive to the mTOR inhibitor rapamycin, University of Pittsburgh scientists have now discovered. Monday, February 4, 2019 Merck & Co.’s endeavor to challenge Prevnar 13, the world’s best-selling vaccine, just got a speed-up. But except for a small head start in phase 3 trials, the blockbuster's would-be rival doesn’t appear to have a big lead over Pfizer, which is developing a 20-strain shot. Wednesday, February 6, 2019 Gilead is looking to eventually sub out HIV drug Truvada with Descovy when it comes to pre-exposure prophylaxis, or PrEP. But in the meantime, it’s socking resources into Truvada. Wednesday, February 6, 2019 Welsh CRO Simbec-Orion was acquired by U.K.-based private equity firm CBPE Capital for an undisclosed price. The deal will provide funding for international expansion for the CRO, particularly in the U.S. and European markets. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: AlphaSense It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 